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Epilepsy andmental illness have a bidirectional association. Psychiatrists are likely to encounter epilepsy as comorbidity.
Seizures may present as mental illness. Equally, the management of psychiatric conditions has the potential to destabilise
epilepsy. There is a need for structured epilepsy awareness and training amongst psychiatrists. This paper outlines key
considerations around diagnosis, treatment and risk while suggesting practical recommendations.
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Introduction
Epilepsy is a common neurological disorder with a
prevalence in Ireland of approximately 1% (Linehan
et al., 2009). The definition of epilepsy has evolved over
the last two decades and an internationally accepted
clinical definition (Fisher et al., 2014) as adopted by the
international league against epilepsy reflects clinical
considerations, risk of further seizures as well as the
issue of disease resolution. While epilepsy is a complex
neurological condition and managed primarily by
neurologists, in this paper we outline diagnostic, ther-
apeutic and risk-related aspects that highlight the rele-
vance of this neurological illness to the practising
psychiatrist.
Epilepsy and mental health
Psychiatrists encounter epilepsy as both a comorbidity
and a differential diagnosis. Olfactory hallucinations in
a patient with psychosis may raise the possibility of
temporal lobe epilepsy (TLE) (Flor-Henry, 1969) or
seizure activity may have a role in challenging beha-
viour in a person with an intellectual disability (Blick-
wedel et al., 2017).
Encountering epilepsy in psychiatric patients is not
uncommon as psychiatric morbidity is over-represented
in individuals with epilepsy with increased rates of
affective disorders (25–74%), anxiety disorders (10–25%)
and psychosis (2–7%) (Jones et al., 2010). A recent Irish
study (Murphy et al., 2018) noted the prevalence of epi-
lepsy in general psychiatric inpatient settings to be over
3%; three times that of general population estimates.
This is perhaps unsurprising as some of these illnesses,
particularly psychotic illness are thought to have a neu-
rodevelopmental origin (Murray & Lewis, 1987). Addi-
tionally, there is evidence of genetic overlap between
psychosis and epilepsy (Clarke et al., 2012).
Epilepsy and psychiatric disorders are individually
related to higher mortality rates. In epilepsy this is
particularly true of those with uncontrolled seizures
(Robertson et al., 2015). The two conditions are also
associated with a higher risk of suicide and other
physical comorbidities.
Epilepsy and people with intellectual disabilities
The prevalence of epilepsy in people with intellectual
disabilities is significantly higher. A recent systematic
review and meta-analysis (Robertson et al., 2015)
showed a pooled epilepsy prevalence of 22.2% (95%
confidence interval 19.6–25.1) in those with intellectual
disabilities with prevalence increasing as the severity of
disability increased. The Royal College of Psychiatrists
has published recent guidance for the management of
epilepsy in those with intellectual disabilities which
recommends epilepsy training as part of higher specia-
list training (HST) for those psychiatrists who specialise
in intellectual disabilities in the United Kingdom (Royal
College of Psychiatrists, 2017b). In Ireland, people with
intellectual disabilities often receive care in general adult
psychiatric settings, particularly where individuals have
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a mild-to-moderate intellectual disability or additionally
if individuals require involuntary treatment. Thus rea-
sonable knowledge of epilepsy concerns in people with
intellectual disability is important across the psychiatric
specialism in Ireland.
Diagnostic issues
Seizures can present as symptoms of mental illness
Complex partial seizures can present as poor impulse
control, ‘rage attacks’, suicide attempts, rapid mood
swings, depression, psychotic episodes, bulimia, panic
attacks, obsessive-compulsive symptoms and somatic
complaints (Stern & Murray, 1984). A patient may be
treated with psychotropic medication for years before
an organic cause is suspected. Herein lies the value of
being alert to epilepsy as a differential diagnosis where
there are atypical presentations, diagnostic over-
shadowing, treatment resistant illness, neurological
signs, history of central nervous system illness such as
encephalitis, a concerning medical history such as one
involving unexplained loss of consciousness or a family
history of seizures.
A particularly important type of seizure that may
present as mental illness is TLE which can present as
psychosis. Psychosis in TLE (Belletsky & Mirsattari,
2012) may have either a relapsing-remitting (concurrent
with seizures) or chronic course (involving interictal
phase) and preictal states may present with an altered
sensorium, including a range of perceptual abnormal-
ities including visual, auditory, olfactory or gustatory
illusions or hallucinations.
Frontal lobe epilepsy can present with behavioural
disturbance, psychiatric symptoms including depres-
sion or psychosis and cognitive changes (Braakman
et al., 2011; Gold et al., 2016); it can be associated with
attention deficit hyperactivity disorder (ADHD) in
children (Braakman et al., 2011).
There may be a relationship between seizure control
and psychotic symptoms in some patients. The term
‘forced normalisation’ is used to describe psychotic
episodes associated with the remission of seizures and
disappearance of epileptiform activity on electro-
encephalogram in individuals with epilepsy (Loga-
nathan et al., 2015). Further there could be psychotic
activity associated with seizures during the pre-ictal,
ictal or post-ictal stages. There could be identified
changes in affect and mood associated with seizures
(Kanner & Rivas-Grajales, 2016). The management of
such psychoses require a careful balance between anti-
epileptic medications, antipsychotic or other psycho-
tropic drugs, with close clinical monitoring and
communication between the patient, their family, and
involved specialities.
In people with intellectual disability presenting with
challenging behaviour, it is important for the treating
clinician to rule out seizure activity given the high rate
of seizure disorder as a comorbidity in this group
(Blickwedel et al., 2017; Roberston et al., 2015). The
assessing clinician may need to consider the role of
factors such as seizure frequency, peri-ictal events and
the role of anti-epileptic drugs (AEDs) additionally in
their formulation (Kerr et al., 2016).
The value of an Electro-Encephalogram (EEG)
An electro-encephalogram (EEG) may be helpful in the
investigation of possible seizure disorder. However,
caution is required in interpretation as either no
abnormal activity or only minimal changes such as
focal slowing or brief patterns of spikes and waves may
be evident even in individuals with diagnosed epilepsy.
The sensitivity of interictal EEG varies from 29–55%
(Pillai & Sperling, 2006) with higher estimates for repeat
examinations and activation techniques whilst specifi-
city is variable with estimates in excess of 90% for some
epilepsy syndromes (Oliviera & Rosado, 2004). Video-
EEGs have significantly greater diagnostic yield (Pillai
& Sperling, 2006). There needs to be specific caution in
interpreting EEGs in people with intellectual disability
as they may have abnormal brain wave patterns linked
to a congenital brain defect or damage.
EEG departments helpfully use photic stimulation,
hyperventilation or sleep deprivation (all of which
lower the seizure threshold) to help evaluate cases
where a referral clearly queries the diagnosis of epi-
lepsy. Video-EEG is the only definite way to diagnose
functional seizures and behavioural disturbance linked
with epileptic activity. This is sometimes limited to
tertiary centres but as an investigation this can be
invaluable in providing diagnostic certainty.
Indications for Magnetic Resonance Imaging (MRI) of
the Brain
Where an organic cause is suspected in individuals
presenting with either behavioural disturbance or
symptoms suggesting a mental illness and particularly
where focal deficits are noted on neurological exam-
ination, magnetic resonance imaging (MRI) of the brain
should be obtained. Brain MRIs are often superior to
Computerised Tomography due to their higher reso-
lution allowing them to identify smaller space occupy-
ing lesions and separate more clearly grey and white
matter. Despite this, a normal MRI of the brain does not
exclude a diagnosis of epilepsy. MRI abnormalities may
be seen in 80% of patients with refractory focal epilepsy
but estimates are four times lower in patients with a
single unprovoked seizure or epilepsy in remission
(Roy & Pandit, 2011).
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Therapeutic issues
Psychotropics and seizure threshold
Seizure thresholds may be affected by the majority of
psychotropic agents, although there is a large variance
between psychotropic agents in relation to such an
effect. As a basic tenet, psychotropic agents that have
sedative effects have an increased likelihood to be
associated with inducing seizures (Taylor et al., 2015).
This is important as even when prescribing anti-
depressants or antipsychotics in a patient with well
controlled epilepsy, there is a potential for destabilisa-
tion which should be highlighted to the patient, his/her
carer and clinical correspondence copied to the con-
cerned neurologist or general practitioner. An effect on
seizure threshold may have implications for driving
and safety in other social situations.
Guidelines are constantly evolving in this area but
the Maudsley Prescribing Guidelines 13th edition
(Taylor et al., 2018) currently state that selective ser-
otonin reuptake inhibitors (SSRIs) (except citalo-
pram), the antidepressant mirtazapine and the
antipsychotic agents risperidone, aripiprazole, halo-
peridol, amisulpiride and sulpiride are associated
with a minimal impact on seizure thresholds and thus
should be considered for the management of mood or
psychotic disorders in individuals with epilepsy.
Caution must also be exercised in discontinuing ben-
zodiazepines, lamotrigine or sodium valproate (when
used as mood stabilisers) as these may be masking
latent seizures in a patient who has well controlled
epilepsy.
ADHD is overrepresented in individuals with epi-
lepsy (Williams et al., 2016). Stimulant medication and
potentially atomoxetine used in the treatment of ADHD
have the potential to reduce seizure threshold (Harpin
et al., 2008).
Anti-Epileptic Drugs (AEDs) and psychiatric/
behavioural manifestations
There is increasing evidence of psychiatric disorders or
behavioural disturbance arising due to treatment with
AEDs. AEDs may be neutral, have positive effects on
the management of mental illness or negative effects
(Nadkarni & Devinsky, 2005; Royal College of Psy-
chiatrists, 2017a). Positive effects of AEDs include, for
example, the antidepressant effect of lamotrigine or
mood stabilising effects of sodium valproate. Negative
effects of AEDs include cognitive problems and
dependence risk with barbiturates and the risk of psy-
chosis and affective disorders with phenytoin and vig-
abatrin. Levetiracetam in particular has been associated
with behavioural disturbance and affective adverse
effects (Abou-Khalil, 2008). Such adverse effects have
been associated with significant AED discontinuation
rates (Stephen et al., 2017).
AED/Psychotropic interactions
Another area of caution when prescribing psycho-
tropics is the potential for pharmacokinetic interactions
through cytochrome P450 enzymes (Taylor et al., 2018).
Some commonly prescribed antidepressants such as
fluoxetine and sertraline at higher doses can increase
anticonvulsant plasma levels. Some anticonvulsants
such as phenytoin and carbamazepine can reduce
plasma levels of psychotropics. Of note, recent gui-
dance for AED prescribing (Royal College of Psychia-
trists, 2017a) advocate against the first line use of older
AEDs such as phenytoin and phenobarbitone in
epilepsy.
Teratogenicity
Sodium valproate can be prescribed both for affective
disorders and seizure control. The use of this medica-
tion is best avoided in women of child bearing age
given its significant teratogenic potential (Ornoy, 2009).
Particular care must be taken with additional safe-
guards such as a clear discussion of risks and benefits as
well as the use of contraception should its use be
necessary, in keeping with recent regulations (Sisodiya,
2018).
Medication adherence
In patients with comorbid mental illness and epilepsy,
non-adherence with prescribed medication has the
potential to precipitate relapse in mental illness and
destabilise seizure control. Both conditions are sepa-
rately known to have limited adherence rates with one
study citing that a third of those with epilepsy may not
be adherent to prescribed medication (Getnet et al.,
2016). Up to 60% of those with psychosis may be non-
adherent at some point over a 4 year follow up period
(Valenstein et al., 2006). Patients may therefore need
suitable education, oversight and support for con-
tinuity with medication.
Specific considerations in people with intellectual
disabilities
The prescription of psychotropic medication in people
with intellectual disabilities requires care due to a lower
threshold for side effects and an increased prevalence of
physical comorbidities. Medication, when clearly indi-
cated, should be used cautiously at lower doses with
specificmonitoring for outcomes and emergence of side
effects. The prescription of antiepileptic medication in
people with intellectual disabilities and epilepsy
requires particular care in respect of issues around
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consent, capacity to consent, the involvement of carers,
monitoring of outcomes and specific choice of medica-
tion (Royal College of Psychiatrists, 2017).
Areas of Risk
Given that psychiatric treatment can potentially desta-
bilise seizure control, a clinician may need to be mind-
ful of the social risk profile that this may create. Alcohol
misuse, for example, is a significant comorbidity with
mental illness (Regier et al., 1990) and carries the risk of
destabilising seizure control (Hillbom et al., 2003).
Driving
Experiencing a seizure whilst driving can risk injury to
the person or other road users. In Ireland, regulations
governing driving for those with epilepsy are pub-
lished by the Road Safety Authority (RSA, 2016) and
this makes an essential reference document for practi-
tioners. They make different recommendations for
those with daytime and nocturnal seizures as well as
some specific aetiologies. The RSA recommends a 12-
month seizure free period prior to recommencing
driving for those with daytime seizures, alongside
other stipulations such as compliance with treatment.
Activities of daily living
Guidance from the National Institute for Health and
Care Excellence (NICE) (2018) highlights the need to be
mindful of risks in those with seizures in activities of
daily living. Such may extend to psychiatric inpatient
settings. Examples would include situations such as
operating electrical equipment and swimming if
undertaken as part of occupational therapy. Bathing
arrangements require special care and showers are
safer than baths in those with seizures. Where the per-
son wishes to bathe, continuous observation during
that timewould be the only measure that mitigates risk.
Risks associated with activities of daily living require
particular care and specialist care planning in people
with intellectual disabilities who aremore likely to have
other physical comorbidities, a greater sensitivity to
changes in medication and require assistance with
communication (Royal College of Psychiatrists, 2017b).
SUDEP
The risk of sudden unexpected death in epilepsy
(SUDEP) is 1 in 1000 person years but can be as high as
1 in 100 person years in those with treatment resistant
epilepsy and uncontrolled seizures (Shankar et al.,
2017). There are potentially modifiable risk factors that
mitigate this risk such as nocturnal monitoring, com-
pliance and advice on sleeping position (Shankar et al.,
2016). For the psychiatrist an awareness of the impact of
treatment adherence and co-morbid alcohol or psy-
choactive substance (ab)use are important due to them
being modifiable risk factors for individuals with epi-
lepsy. Some studies suggest that intellectual disabilities
are a risk factor for SUDEP (Young et al., 2015). Spe-
cialist advice from a neurologist may be helpful when
considering the prescription of new psychotropic in
those with poorly controlled seizures and this is parti-
cularly important in those with comorbid intellectual
disabilities. A good tool to inform patients of their risk
of SUDEP is the SUDEP and Seizure Safety Checklist
(SUDEP Action, 2017).
Management of prolonged seizures
Doctors working in psychiatry may find themselves
responding to a prolonged seizure for an inpatient or
working with patients who have a history of past status
epilepticus. The management of such can often be fore-
seen and a history at the time of admission is often the
best time to prescribe a ‘rescue medication’ on an ‘as
required’ basis. Buccalmidazolammay be safer andmore
acceptable to patients than other modalities of benzodia-
zepine use (Scott et al., 1999). Training in administering
midazolam and the other aspects of emergency care in
status is invaluable for first responders.
Discussion
Epilepsy is a prevalent neurological disorder that is
over-represented in patients in psychiatric services
(Murphy et al., 2018). Patients with epilepsy report
uncertainty for their future and describe the fear of
having a seizure as the ‘worst thing about having epi-
lepsy’ and as important as the limitations in lifestyle,
school, driving and employment that may occur with
this diagnosis (Fisher et al., 2000). Carers for those with
epilepsy have a high level of knowledge (McEwan et al.,
2007) around epilepsy and can be an invaluable source
of information when assessing a patient and this is
particularly true for patients with an intellectual dis-
ability (Espie et al., 2003) where there may be special
needs around communication. A diagnosis of epilepsy
has been demonstrated to not alone reduce the quality
of life of the patient but also adversely impact on the
quality of life of the care-givers (Guti-Errez et al., 2018).
A psychiatrist should be alert to the bi-directional
impact of mental illness and physical illness on each
other. The spectrum of physical illness that a psychia-
trist particularly needs to be aware of includes endo-
crine, metabolic, cardiac and neurological disorders.
Epilepsy is one such neurological disorder at the inter-
face of medical specialities that requires particular care
in view of its higher mortality and complex risk profile.
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Simple interventions and effective communication has
the potential to offer incremental benefit for patients in
diagnosis, therapeutics and risk management.
A useful aid for key aspects of history and manage-
ment considerations for patients with epilepsy in psy-
chiatric inpatient settings is presented as Table 1. This
has been formalised into a diagnosis triggered tool
which has been piloted in Irish settings (Murphy et al.,
2017; Moloney et al., 2017) and is attached as supple-
mentary online material to this article. Additional
sources of advice for psychiatrists when managing a
patient with comorbid epilepsy are included as an
online appendix.
There is substantial training for neurologists in rela-
tion to epilepsy both in basic and HST schemes and this
is a disorder managed primarily by consultant neurolo-
gists, often in tertiary centres. There is a need for
increased awareness of this disorder as a comorbidity in
the psychiatric setting (Murphy et al., 2018). With
awareness and a systematic approach to assessment, this
may be an area where psychiatric expertise can con-
tribute to safer and better lives for people with epilepsy.
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